These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38845210)

  • 1. Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models.
    Heikal OS; van Rheenen PF; Touw DJ; Kosterink JGW; Maurer M; Koomen JV; Chelle P; Mian P
    Br J Clin Pharmacol; 2024 Sep; 90(9):2200-2214. PubMed ID: 38845210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
    Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
    Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
    Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
    Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.
    Bauman LE; Xiong Y; Mizuno T; Minar P; Fukuda T; Dong M; Rosen MJ; Vinks AA
    Inflamm Bowel Dis; 2020 Feb; 26(3):429-439. PubMed ID: 31287855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease.
    Bevers NC; Keizer RJ; Wong DR; Aliu A; Pierik MJ; Derijks LJJ; van Rheenen PF
    Clin Pharmacokinet; 2024 Apr; 63(4):529-538. PubMed ID: 38488984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.
    Berends SE; D'Haens GRAM; Schaap T; de Vries A; Rispens T; Bloem K; Mathôt RAA
    Br J Clin Pharmacol; 2019 Jul; 85(7):1544-1551. PubMed ID: 30927375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model.
    Clemente-Bautista S; Trocóniz IF; Segarra-Cantón Ó; Salvador-Marín S; Parramón-Teixidó CJ; Álvarez-Beltrán M; López-Fernández LA; Colom H; Cabañas-Poy MJ; Gorgas-Torner MQ; Miarons M
    Paediatr Drugs; 2024 May; 26(3):331-346. PubMed ID: 38507036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
    Borren NZ; Paulides E; Frinack JL; Olson RN; Willrich MAV; van der Woude CJ; Ananthakrishnan AN
    Dig Dis Sci; 2021 Oct; 66(10):3548-3554. PubMed ID: 33037969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling.
    Kimura K; Yoshida A; Katagiri F; Takayanagi R; Yamada Y
    Eur J Pharm Sci; 2020 Jul; 150():105317. PubMed ID: 32205229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab in young paediatric IBD patients: it is all about the dosing.
    Jongsma MME; Winter DA; Huynh HQ; Norsa L; Hussey S; Kolho KL; Bronsky J; Assa A; Cohen S; Lev-Tzion R; Van Biervliet S; Rizopoulos D; de Meij TGJ; Shouval DS; Wine E; Wolters VM; Martinez-Vinson C; de Ridder L;
    Eur J Pediatr; 2020 Dec; 179(12):1935-1944. PubMed ID: 32813123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
    Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
    Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.
    Dave MB; Dherai AJ; Desai DC; Mould DR; Ashavaid TF
    Eur J Clin Pharmacol; 2021 Jan; 77(1):55-62. PubMed ID: 32803288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    J Crohns Colitis; 2018 Nov; 12(11):1316-1325. PubMed ID: 30239644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
    Merras-Salmio L; Kolho KL
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy.
    van Hoeve K; Seyed Tabib NS; Dreesen E; Tops S; Hoffman I; Gils A; Ferrante M; Vermeire S
    J Pediatr; 2022 Jan; 240():150-157.e4. PubMed ID: 34481805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.
    Liefferinckx C; Minsart C; Toubeau JF; Cremer A; Amininejad L; Quertinmont E; Devière J; Gils A; van Gossum A; Franchimont D
    Inflamm Bowel Dis; 2017 Aug; 23(8):1371-1381. PubMed ID: 28498153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.
    Coutzac C; Chapuis J; Poullenot F; Chabrun E; Capdepont M; Blanco P; Laharie D
    J Crohns Colitis; 2015 Nov; 9(11):982-7. PubMed ID: 26351388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease.
    Frymoyer A; Hoekman DR; Piester TL; de Meij TG; Hummel TZ; Benninga MA; Kindermann A; Park KT
    J Pediatr Gastroenterol Nutr; 2017 Dec; 65(6):639-645. PubMed ID: 28471911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.